New hope for kids with resistant cancers: targeted drug enters trial

NCT ID NCT07630974

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 11 times

Summary

This study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about 134 children with specific cancer types.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ifinatamab deruxtecan (I-DXd)
What this could lead to: If it works, this could offer a new treatment option for children with hard-to-treat solid tumors that have come back or not responded to standard therapy.
What could go wrong: This is an early-phase trial with a small number of children, so results may not apply to all patients. The drug may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm neuroblastoma osteosarcoma rhabdomyosarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 4973)
RECRUITING

Seoul, 05505, South Korea
Bordeaux University Hospital - Pellegrin ( Site 4105)
RECRUITING

Bordeaux, Aquitaine, 33076, France
CENTRE LEON BERARD ( Site 4100)
RECRUITING

Lyon, Rhone, 69373, France
Children's Hospital of Philadelphia (CHOP) ( Site 4021)
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Dana Farber Cancer Center ( Site 4013)
RECRUITING

Boston, Massachusetts, 02215, United States
Hospital Niño Jesús ( Site 4715)
RECRUITING

Madrid, Madrid, Comunidad de, 28009, Spain
Hospital Sant Joan de Déu ( Site 4717)
RECRUITING

Esplugues de Llobregat, Barcelona, 8950, Spain
Hospital Universitari Vall d Hebron ( Site 4716)
RECRUITING

Barcelona, 08035, Spain
Intermountain - Primary Children's Hospital ( Site 4014)
RECRUITING

Salt Lake City, Utah, 84113, United States
Memorial Sloan Kettering Cancer Center ( Site 4010)
RECRUITING

New York, New York, 10065, United States
New York Medical College ( Site 4023)
RECRUITING

Valhalla, New York, 10595, United States
Rambam Health Care Campus ( Site 4674)
RECRUITING

Haifa, 3109601, Israel
Rigshospitalet ( Site 4467)
RECRUITING

Copenhagen, Capital Region, DK-2100, Denmark
Rutgers Cancer Institute of New Jersey ( Site 4008)
RECRUITING

New Brunswick, New Jersey, 08901, United States
Sahlgrenska Universitetssjukhuset ( Site 4634)
RECRUITING

Gothenburg, Västra Götaland County, 416 85, Sweden
Seoul National University Hospital-Pediatrics ( Site 4972)
RECRUITING

Seoul, 03080, South Korea
Sheba Medical Center ( Site 4675)
RECRUITING

Ramat Gan, 5265601, Israel
UZ Gent ( Site 4428)
RECRUITING

Ghent, Oost-Vlaanderen, 9000, Belgium
University of Iowa Hospitals ( Site 4017)
RECRUITING

Iowa City, Iowa, 52242, United States
University of Texas M.D. Anderson Cancer Center ( Site 4007)
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.